Jpmorgan Chase & CO Clearside Biomedical, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,419 shares of CLSD stock, worth $10,627. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,419
Previous 10,585
1.57%
Holding current value
$10,627
Previous $16,000
18.75%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CLSD
# of Institutions
54Shares Held
13.4MCall Options Held
17.6KPut Options Held
100-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.9 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.24 Million3.43% of portfolio
-
Armistice Capital, LLC New York, NY2.14MShares$2.18 Million0.04% of portfolio
-
Carmignac Gestion Paris, I02.13MShares$2.18 Million0.05% of portfolio
-
Black Rock Inc. New York, NY798KShares$814,0990.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $61.4M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...